External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

HealthCare Global Enterprises / Equity Bottom-Up

<ul><li>Healthcare Global Enterprises (HCG) reported revenue Rs 358 Cr grew by 30.7% YoY which is in line with expectations.</li><li>This growth is primarily led by healthy ARPOB (Rs 38,320) that has shown growth of 15.8% YoY and the number of occupied bed days grew by 17% YoY</li><li>We recommend “BUY” with a target price of Rs 330.</li></ul><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Healthcare Global Enterprises (HCG) reported revenue Rs 358 Cr grew by 30.7% YoY which is in line with expectations.This growth is primarily led by healthy ARPOB (Rs 38,320) that has shown growth of 15.8% YoY and the number of occupied bed days grew by 17% YoYWe recommend “BUY” with a target price of Rs 330.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HealthCare Global: High-End Work Improves Realisations

<ul><li>We initiate coverage on HealthCare Global Enterprises Ltd (HCG) with a BUY rating and a target price of Rs 330, implying an upside potential of 32% from the current levels.</li><li>Oncology opportunity growing faster than the Healthcare market Oncology, with a 13% CAGR over FY16-19, is the fastest growing industry in the Healthcare market</li><li>HCG is expected to turn around its operating profitability with Operating EBITDA Margins improving by 680bps over FY21-FY24E</li></ul><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We initiate coverage on HealthCare Global Enterprises Ltd (HCG) with a BUY rating and a target price of Rs 330, implying an upside potential of 32% from the current levels.Oncology opportunity growing faster than the Healthcare market Oncology, with a 13% CAGR over FY16-19, is the fastest growing industry in the Healthcare marketHCG is expected to turn around its operating profitability with Operating EBITDA Margins improving by 680bps over FY21-FY24EContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Health.Global: Leadership in Speciality Healthcare; Operating Profitability Turning Around

External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

<p>About the stock: HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. This consists of 22 comprehensive cancer centres that provide a single point destination for complete cancer care.</p>
<ul>
<li>Most centres are on a lease or rental basis with some in partnership with local doctors or hospitals</li>
<li>Owing to exclusive agreement with vendors, HCG procures equipment on a deferred payment basis</li>
</ul>
<div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

About the stock: HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. This consists of 22 comprehensive cancer centres that provide a single point destination for complete cancer care.

Most centres are on a lease or rental basis with some in partnership with local doctors or hospitals
Owing to exclusive agreement with vendors, HCG procures equipment on a deferred payment basis

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Healthcare Global Enterprises: Recovery in Q1 with Better Margins

India

HealthCare Global Enterprises is a leading healthcare provider in India, specializing in comprehensive cancer diagnosis and treatment, including medical oncology, radiation therapy, and surgical oncology. The company also offers fertility treatments under the Milann brand, advanced screening and diagnostic services, and multi-specialty hospital care. It was founded in 1989 (initially as Bangalore Institute of Oncology) and is headquartered in Bangalore, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

HealthCare Global Enterprises (HCG IN)

HealthCare Global: High-End Work Improves Realisations

Healthcare Global Enterprises (HCG) reported revenue Rs 358 Cr grew by 30.7% YoY which is in line with expectations. We recommend BUY with a target...

Axis Direct

Health.Global: Leadership in Speciality Healthcare; Operating Profitability Turning Around

We initiate coverage on HealthCare Global Enterprises Ltd (HCG) with a BUY rating and a target price of Rs 330 (EV/EBITDA 15x for FY24E EBITDA),...

Axis Direct

Healthcare Global Enterprises: Recovery in Q1 with Better Margins

HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. This...

ICICI Securities Limited

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)